Phone: 959-333-0983
Phone: 959-333-0983
$54.99
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
Ipamorelin is examined in research settings as a selective growth hormone secretagogue peptide, designed to interact with the GHS-R (ghrelin receptor). Research involving Ipamorelin focuses on ligand–receptor binding behavior, signal initiation, and downstream intracellular signaling pathways under controlled experimental conditions.
This compound is supplied exclusively for scientific and analytical research and is not intended for consumer, clinical, or therapeutic use.
$54.99
Synthetic Growth Hormone Secretagogue Peptide
Ipamorelin is a synthetic pentapeptide supplied exclusively for laboratory and analytical research purposes. This compound is studied in controlled research environments for its interaction with growth hormone secretagogue receptors (GHS-R) and its role in peptide-mediated endocrine signaling models.
Each batch of Ipamorelin is independently third-party tested to verify identity and purity, supporting accuracy and reproducibility in scientific research applications.
Ipamorelin is studied in laboratory and preclinical research environments to better understand peptide-based activation of growth hormone secretagogue receptors with high selectivity. Researchers examine this compound to explore:
As a short and well-characterized peptide, Ipamorelin allows researchers to investigate receptor signaling behavior with precise experimental control.
In experimental models, Ipamorelin binds to the growth hormone secretagogue receptor (GHS-R), initiating intracellular signaling cascades associated with G protein–coupled receptor activation. Research focuses on signal transduction pathways, receptor activation dynamics, and regulatory feedback mechanisms within endocrine signaling systems.
These investigations are mechanistic and exploratory and do not imply physiological, therapeutic, or performance-related outcomes.
Ipamorelin supplied by ResearchChemical.com is produced under controlled peptide synthesis conditions to support compound integrity, purity, and reproducibility.
Manufacturing and verification standards include:
These measures ensure transparency and reliability for laboratory research use.
Laboratory supplies and dilution solutions are not included.
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.
Store Ipamorelin in a cool, dry environment away from direct light. Refrigerate after reconstitution, if applicable, to maintain peptide stability. Avoid repeated freeze-thaw cycles and follow standard laboratory handling protocols to prevent contamination or degradation.
By purchasing from ResearchChemical.com, you acknowledge that you are acquiring research chemicals intended solely for scientific investigation.
Ipamorelin is:
The information provided on this page is for educational and informational purposes only and should not be interpreted as medical advice. ResearchChemical.com assumes no liability for misuse, improper handling, or use outside of controlled research environments. It is the purchaser’s responsibility to ensure compliance with all applicable laws and regulations.
Ipamorelin is a growth hormone secretagogue that stimulates the release of GH from the pituitary gland. It has potential implications in promoting overall growth, bone formation, and lean muscle mass, but further research must be conducted to confirm these preliminary findings.
Yes, the ghrelin mimetic ipamorelin is known to increase GH levels and stimulate growth hormone release from the pituitary gland.
Research suggests that the growth hormone releasing hormone ipamorelin may have a favorable safety profile, as it is well-tolerated in laboratory and research use. However, more comprehensive clinical trials are needed to ascertain any potential negative side effects.
According to recent research, Ipamorelin’s operational mechanics enable it to increase GH levels, which may support body weight regulation and promote lean muscle tissue, contributing to potential weight loss.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.
By purchasing from ResearchChemical.com, you acknowledge that you are acquiring research chemicals intended solely for scientific investigation.
Ipamorelin is:
The information provided on this page is for educational and informational purposes only and should not be interpreted as medical advice. ResearchChemical.com assumes no liability for misuse, improper handling, or use outside of controlled research environments. It is the purchaser’s responsibility to ensure compliance with all applicable laws and regulations.
1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective GH secretagogue. European Journal of Endocrinology. 1998 Oct;139(5):552-61. doi: 10.1530/eje.0.1390552.
2. Johansen, P. B., Nowak, J., Skjærbæk, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Ørskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
3. Vahl, N., Juul, A., Jørgensen, J. O., Ørskov, H., Skakkebæk, N. E., & Christiansen, J. S. (2000). Continuation of GH replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism, 85(5), 1874-1881.
4. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., … & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of GH secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149.
5. Horvath, T. L., Castañeda, T., Tang-Christensen, M., Pagotto, U., & Tschop, M. H. (2003). Ghrelin as a potential anti-obesity target. Current Pharmaceutical Design, 9(17), 1383-1395.
6. Sjögren, K., Jansson, J. O., Isaksson, O. G., & Ohlsson, C. (2002). A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I. Endocrine, 19, 249-256.
7. D’Agostino, P. IGF-1 LR3: The rapid-acting GH alternative.
8. Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-37.
9. Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 25(6), 403-406.
10. Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272.
Please note that the above references provide evidence for the potential benefits of Ipamorelin Peptide as stated in the product description. For more in-depth information, refer to these scholarly works.
Join our insider list for the latest research insights, product releases, and special offers—delivered straight to your inbox.